Here's What You May Have Missed About Cytokinetics(CYTK)

By Emilio Sanchez • Wednesday, February 28 15:12 • Permanent Link

Cytokinetics sank -8.2% today. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Cytokinetics has moved 87.9% over the last year, and the S&P 500 logged a change of 28.5%
CYTK has an average analyst rating of buy and is -22.47% away from its mean target price of $95.94 per share
Its trailing earnings per share (EPS) is $-5.55
Cytokinetics has a trailing 12 month Price to Earnings (P/E) ratio of -13.4 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.3 and its forward P/E ratio is -22.5
Cytokinetics is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.